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2Abstract 
Reactive oxygen species (ROS) have been implicated in the pathogenesis of many 
colonic diseases. Mucus is the colon's first line of defence against luminal agents. This 
study has therefore characterised ROS action on colonic mucus secretions. 
ROS were produced using peroxide-based systems of different concentrations. 
The effects of these systems were tested on native colonic mucus gels, isolated colonic 
mucins, and in vivo models. 
Colonic mucus gels were resistant to ROS breakdown. Mucins were susceptible to 
ROS attack, causing loss of terminal sugars and  protein and mucin fragmentation. The in
vivo thickness of the mucus barrier was reduced by up to 50% by ROS (above 5mM 
peroxide).  5mM peroxide caused a significant increase in resting mucus thickness of 
c.15%. All ROS generating stystems caused mucosal damage once the loosely adherent 
mucus had been removed. 
As native mucus gel is more resistant to ROS damage than purified mucin, non-
mucin components of mucus may have extensive ROS scavenging properties. Low levels 
of luminal colonic ROS increase the protection afforded by the mucus barrier in vivo.
Higher levels of ROS significantly reduce this protection. In vitro modeling of mucus 
degradation by ROS does not necessarily correlate with the dynamic, in vivo situation.
3Introduction
A continuous mucus layer lines the mucosal surface of the lower bowel, 
protecting the mucosa, while at the same time lubricating the passage of luminal contents, 
thus lowering shear stress induced damage [1]. These actions help to maintain mucosal 
integrity. The barrier-like functions of the mucus layer are elicited by its functional 
component, mucin, which makes up about 4% of the weight of the mucus gel [2]. In 
effect, the colonic mucus barrier acts as the colon’s first line of defence against the wide 
range of potentially damaging agents that occur within the lumen.  
One type of damaging agent that has been hypothesised to occur within the 
colonic lumen are Reactive Oxygen Species (ROS) [3]. Increased ROS activity has been 
linked to a number of colonic disorders, most notably ulcerative colitis [4, 5]. Increased 
levels of oxidant stress and decreased levels of antioxidant defence are witnessed in the 
colonic tissue of active UC patients [5-10].  
In active UC, the thickness and continuity of the colonic mucus barrier has been 
shown to be reduced [11-13]. Mice deficient of Muc-2, the gene that encodes for the 
major intestinal secreted mucins, have been reported to spontaneously develop colitis 
after 5 weeks [14], demonstrating the importance of the colonic mucus barrier in 
preventing ulcerative colitis. A number of in vitro studies have shown the gastric mucins 
of various species to be degraded by the presence of ROS [15-19]. The colonic mucus gel 
may behave differently to gastric mucus as it contains mucins with a higher negative 
charge and larger quantities of bacterial cells, both of which could have a role in ROS 
quenching [20]. Colonic mucus may be subjected to elevated ROS produced within the 
intestinal lumen, either as a result of dietary components (e.g. high iron [21] or low 
fibre/high fat [3]), release of endogenous, ROS producing enzymes from sloughed cells, 
such as xanthine and aldehyde oxidases [22, 23]. or via infiltration of neutrophils and 
macrophages towards the colonic epithelium [24].  
Increased levels of metabolites of anaerobic colonic bacteria [25] may also bring 
about an raised ROS levels. Further from this, higher counts of aerobic bacteria have also 
4been suggested to occur in the mucosa-associated microflora of paediatric patients with 
inflammatory bowel disease [26] and faeces of ulcerative colitis patients [27]. The 
colonic mucus layer could protect from luminal ROS by increasing the diffusion distance 
from the lumen to the mucosa, as well as acting to directly quench ROS before they cause 
damage to the underlying mucosa. 
Whether the increase in oxidative stress to the colon and the thinning of the 
colonic mucus barrier seen in UC is the cause, or is an effect of, the disease process 
remains unclear. For luminal ROS to cause damage to the colonic mucosa, we 
hypothesize that it must first reduce the protective potential of colonic mucus. To test 
whether this occurs, this paper aimed to determine the effects of ROS on polymeric 
colonic mucins, the native gel layer in vitro, and also in an in vivo colonic mucus barrier, 
thereby aiming to demonstrate the molecular and macroscopic effects that increased 
colonic ROS could have on mucus barrier integrity in vivo.
Materials & Methods 
Porcine colonic mucus/mucins has previously been reported to be biochemically 
and biophysically similar to human colonic mucus/mucins [28, 29], whilst isolated rat 
colonic mucins have a similar buoyant density and amino acid content to human colonic 
mucins, while also showing cross-reactivity to antibodies initially raised to the human 
MUC2 gene product [30].   In these studies, porcine colonic mucus was used as a source 
of native gel and polymeric mucin for in vitro studies, as a large quantity is required for 
this type of experimentation. In vivo work was carried out using a rat model. 
Degradation of native mucus gels by ROS
Porcine colons were collected on ice from a local abattoir. 3 g of mucus gel, 
scraped from the surface mucosa, was placed at the bottom of a glass vial and held down 
with a circular wide mesh plastic gauze.  A 10 ml volume of phosphate buffered saline, 
5pH 7.4, containing the ROS generating components 50 mM H2O2 + 0.5 mM FeSO4 and 
0.5 mM EDTA, was transferred to the vial and stirred gently.  Control experiments were 
carried out using phosphate buffered saline, pH 7.4, alone as the test solution. 
Three samples (1 ml) of bathing solution were removed at intervals over 5 h 
incubation at 37
o
C and not replaced (see Figure 1). Samples were centrifuged at 320g for 
2 minutes at 4
o
C to remove insoluble material and exhaustively dialysed, then analysed 
for solubilised glycoprotein by the Periodic acid-Schiff’s (PAS) method [31]. Sepharose 
CL-2B analysis was used to assess the hydrodynamic size of porcine colonic mucin-
degradation products. 
In separate studies, native mucus gels were homogenised in small quantities of 
PBS for 1 minute using a Waring blender. This liquid was then centrifuged  (8000g at 
4
o
C for 1 hour) to remove particulate matter, and adjusted to a glycoprotein content of 5 
mg.ml
-1
 (as assayed by PAS method [31]), by dilution with further PBS. 
Effects of ROS on rheological properties of native mucus gels
Rheological properties of native colonic mucus were assessed using a Bohlin 
CVO-50 rheometer with a 40 mm parallel plate geometry, set at a gap width of 1 mm, 
and operating in oscillatory mode. Sample temperature was maintained at 25
o
C by a 
thermostatically controlled circulating water bath. After loading, all samples were 
allowed to equilibrate (5 min) to the measuring temperature and to relax from any 
stresses that may have been induced by the loading pressure. Frequency sweeps were 
carried over frequency range of 0.1 - 3 Hz, at a stress level within the shear independent 
plateau. 
ROS scavenging ability of colonic mucus secretions
A previously described assay system based on the colorimetric oxidative changes 
over time of deoxyribose [32] was used to compare the ROS scavenging ability of the 
native mucus gel, as well as purified polymeric mucin and papain-digested mucin [31]. 
6Effects on purified colonic mucins
Polymeric porcine colonic mucin was prepared by previously described methods 
[28].  Effects of ROS on the viscosity of 5 mg/ml solutions of porcine colonic mucin 
were assessed using  Contraves Low Shear Couette viscometry over 24 h. 
Amino acid and hexosamine analysis was carried out using reverse-phase HPLC. 
Briefly, mucins are hydrolysed to yield free amino acids/ hexosamines, which were then 
derivatised with phenylisothiocyanate (PITC) to produce phenylthiocarbamyl (PTC) 
amino acids/hexosamines. PTC-products are then analysed by reverse-phase HPLC. 
The glycosylation pattern of ROS breakdown products of colonic was assessed by 
a modification of the enzyme-linked lectin assay (ELLA) described by Baldwin et al.,
(1999) [33]. Purified mucins (0.3 µg/ml carbohydrate) in neutral sodium phosphate buffer 
were coated onto Nunc-immuno Maxisorp 96-well plates. After triplicate washes with 
0.05% Tween20 in PBS, 100µl of a range of biotinylated lectins (in PBS with 0.05% 
Tween20 and 3% bovine serum albumin; see legend on Figure 4 for further details and 
specificities of the lectins used) was added to each well. All other ELLA techniques were 
carried out as previously described [33]. Papain digestion of purified mucins was carried 
out using previously reported methods [34] 
Effects on in vivo mucus layer
The effect of ROS on the intact, in vivo colonic mucus layer thickness was 
assessed using a modified intravital microscopy technique in male Wistar rats [1, 35]. 
This model is currently the only one available which allows measurement of the 
gastrointestinal mucus layer in a whole, in vivo mammalian organism [36, 37]. Further 
from this, this methodology has been shown to give similar measures of adherent mucus 
layer thickness to the tissue-staining methods using minimal dehydration [37, 38]. 
Previous studies have also used this technique successfully to test the effect of a number 
of luminal and dietary agents on rates of mucus secretion and in vivo mucus barrier 
thickness [39-41]. This model therefore represents a novel way of looking at ROS action 
on in vivo mucus barrier thickness, as well as any effects ROS may have at a mucosal 
7level (i.e. on the cellular secretion processes of the colonic mucus barrier). As this model 
is robust, physiological concentrations of ROS can be utilised, which is not possible in 
more fragile cell culture models. 
Mucus thickness was initially measured every 10 min under a bathing solution of 
0.9% saline for 1 h to assess maximal mucus thickness. After this time, the bathing fluid 
was removed, and replaced with a solution containing a peroxide-Fe
++
/EDTA ROS 
generating system (described above) for a further 4 h. The changes in percentage mean 
mucus thickness for each concentration of peroxide (n = 5) were compared to those in a 
saline control group (n = 5). The loosely adherent mucus layer was removed (also n = 5) 
by suction in separate studies, prior to the application of the ROS generating system. 
Results 
After 1 h incubation in control solution (PBS), 3 g of colonic mucus gel 
released 1.35 ± 0.25 mg (n = 3) of soluble glycoprotein into solution. After 5 h, 
this total amount was 2.1 ± 0.1 mg (n = 3). No detectable difference in 
glycoprotein release was seen upon incubation of 3 g colonic mucus with a ROS 
generating mixture of 50mM H2O2, 0.5mM FeSO4/EDTA (1.25 ± 0.15 mg after 1 
h and 2.0 ± 0.1 mg after 5 h). A two-tailed, paired t-test showed that PBS and 
ROS-treated colonic mucus samples did not release significantly different 
amounts of PAS-positive material (P = 0.058). 
The mechanical spectrum of freshly scraped porcine colonic mucus gel is 
shown in Figure 1(A).  Throughout the frequency range accessed, the storage 
modulus, G′, was substantially higher than the loss modulus, G′′. The absolute 
values of the storage and loss moduli varied from sample to sample.  For example, 
at a fixed frequency of 3.4 Hz, the storage modulus and loss modulus varied from 
136 – 315 Pa and 22 – 41 Pa respectively.  Observed values for δ were in the 
range 5.7 – 9.1 (tan δ of 0.1 – 0.16) throughout the frequency range accessed, 
indicative of a strong gel.   
8After ROS treatment (50 mM H2O2 for 5 h) of mucus gel, there was no 
significant change to the absolute values of the storage and loss moduli 
throughout the frequency range accessed (P>0.2) (Figure 1 Graph B).  
Furthermore, after ROS treatment tan δ (0.12–0.16) was not significantly different 
from the untreated control (P>0.8).   
As with the native gel, solubilised colonic mucus gel, containing 5 mg.ml
-1
glycoprotein, (specific viscosity of 2.5), showed resistance to breakdown by ROS 
as seen by the lack of any difference in viscosity at 24h between the control and 
ROS treated samples (figure 2). In addition SDS-PAGE analysis of the 24 h 
samples showed no difference in mucin degradation as assessed by comparing the 
% of polymeric mucin (i.e. 65 ± 2 % vs. 63 ± 2% for non-treated and treated 
samples respectively).Purified undigested colonic mucin (5 mg.ml
-1
) had a 
specific viscosity at time 0 of 4.91 ± 0.14 (n=3) at 37oC in phosphate buffered 
saline, pH 7.4.  The specific viscosity of the untreated colonic mucin control 
dropped by 21 ± 9.7 % after 24 h incubation. In contrast, after ROS treatment of 
colonic mucin with 50 mM H2O2 a rapid fall in mucin specific viscosity over the 
first hour of incubation was followed by a slower fall over the subsequent 24 
hours (Figure 3).  Within 20 minutes of ROS treatment mucin specific viscosity 
had fallen by 46 ± 3.5 % with a further drop to 71 ± 3.1% after 1 hour.  After 24 
hours ROS treatment only 3 ± 0.6 % of initial mucin specific viscosity remained 
compared to 79 ± 9.7 % for the untreated mucin control.  Reducing the level of 
ROS generating components from 50 mM H2O2 to 10 mM H2O2 substantially 
reduced the rate of fall in mucin specific viscosity within the first four hours 
(Figure 3).  After four hours incubation with 10 mM H2O2 mucin specific 
viscosity had dropped by 39 ± 7.2 %, whereas a similar drop was observed after 
only 15 minutes with 50 mM H2O2.  After 24 hours incubation with 10 mM H2O2,
18 ± 2.8 % of initial mucin specific viscosity remained compared to 79 ± 9.7 % 
for the untreated mucin control. 
9After ROS treatment mucin samples were exhaustively dialysed, freeze-dried and 
reconstituted in 0.2 M NaCl/0.02 % NaN3, pH 5.5. Intrinsic viscosity was 
determined at 25
o
C over a range of mucin concentrations by serial dilution. 
Intrinsic viscosity gives information on molecular size, shape and expansion in 
solution. The intrinsic viscosity of purified undigested colonic mucin was 0.391 
ml.mg
-1
.The effect of ROS on purified undigested colonic mucin intrinsic 
viscosity is shown in Table 1.  After 24 h ROS treatment with 10 mM H2O2
intrinsic viscosity of mucin fragments was 0.129 ml.mg
-1
, which is 67% lower 
than the untreated mucin control.  After ROS treatment with 50 mM H2O2, the 
intrinsic viscosity of mucin fragments was 0.036 ml.mg
-1
 (91% lower than the 
untreated mucin control). After proteolytic digestion of purified colonic mucin 
there was large fall in intrinsic viscosity (Table 1).  The intrinsic viscosity of 
papain digested colonic mucin was 0.107 ml.mg
-1
, (~4 fold lower than that of 
undigested colonic mucin). 
ROS treatment of papain digested colonic mucin produced a further fall in 
intrinsic viscosity. Following ROS treatment with 10 mM H2O2 intrinsic viscosity 
of mucin fragments was 0.047 ml.mg
-1
. 50 mM H2O2 ROS treatment gave an 
intrinsic viscosity of 0.014 ml.mg
-1
 (87 % lower than that of papain digested 
mucin, and 61 % lower than that of mucin fragments generated after ROS 
treatment of undigested mucin with 50 mM H2O2).
Mucin fragments generated after ROS treatment of undigested mucin with 50 mM 
H2O2 had an average intrinsic viscosity 66 % lower than that  of papain digested 
mucin, indicating ROS treatment smaller fragments than those generated by 
papain digestion alone. 
These large changes in molecular size of mucins also involve loss polymeric 
structure as evidenced by SDS PAGE (data not shown). Native colonic mucin was 
79 ± 4 % (n=4) polymeric, papain digestion resulted in complete loss of 
polymeric structure and the generation of mucin subunits, relative mobility 0.16. 
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10 mM H2O2, treatment for 24h caused a 50% loss of polymeric structure and 50 
mM H2O2 gave a 100% loss of polymeric structure. Evidence for species smaller 
than those produced by papain were seen as a front of PAS positive material 
running into the gel up to a relative mobility of 0.85.
Changes in glycosylation patterns on ROS treatment of purified undigested 
colonic mucin are shown in Figure 4. 
To summarise, ROS treatment of purified undigested colonic mucin brought 
about reductions in reactivity with the majority of tested lectinsthat bound to the 
carbohydrate structures. However, the reactivities of the fucose specific lectins 
UEA and AAL, and the reactivity of the GlcNAc specific lectin WGA did not 
change. These results suggest that ROS damage leads to loss of terminal sugars 
(i.e. sialic acid and GalNAc), and a significant, but more modest loss of internal 
sugar structures (i.e. galactose, N-acetylglucosamine).  
In terms of destruction of the mucin protein core Table 2 shows that ROS 
treatment caused a significant loss of arginine, histidine, lysine,  isoleucine, 
leucine, phenylalanine, tyrosine and methionine residues. The loss of these amino 
acids from the MUC gene product protein core caused a 6% reduction in total 
protein by weight. Histidine appeared the most susceptible to ROS attack, with 
63% loss of this residue. 
In order to determine the ROS quenching properties of the mucus gel verses the 
mucin components, the ability of ROS to oxidise deoxyribose was assessed with 
and without the presence of the mucus/mucin preparations. As can be seen from 
Table 3 all the preparations were able to reduce the oxidation of deoxyribose to 
some extent, therefore acting as ROS quenchers. 
This quenching ability was concentration dependent. The solubilised mucus gel 
was the best quencher followed by the purified polymeric mucin and the purified 
papain digested mucin subunit was the worst. This suggests that components other 
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than mucin are important in quenching ROS and that the quenching ability of 
mucin is reduced by removal of exposed protein.   
In order to determine the direct effects of ROS on the colonic mucus layer and 
mucosa in vivo, solutions containing peroxide at 5mM, 10mM, 25mM and 50mM 
were applied to both the intact rat colonic mucus layer (having reached maximal 
thickness) and a depleted mucus layer (loosely adherent mucus removed by 
suction to leave only the underlying, adherent mucus layer). The results are 
displayed below in terms of percentage of initial mean mucus thickness, and are 
compared to saline controls (Figure 5).  
Due to variation in the resting mucus thickness between each group, results were 
expressed as a percentage of their median resting mucus thickness. Statistical 
analysis showed that, in the presence of 5 mM peroxide, mucus thickness 
significantly increased above its resting levels (mean % of resting thickness = 
111.4 ± 1.4% vs. control values of 99.3 ± 0.6%). 10 mM peroxide showed no 
significant difference (96.8 ± 1.1%), and 17.5 mM, 25 mM and 50 mM caused a 
significant decrease in mucus thickness from the resting levels (at a rate of 
approximately 10, 11.9 and 12.4%/ h respectively). 
.To test the ability of the colonic mucus layer to regenerate itself, the non-
adherent mucus layer was removed and the underlying adherent layer exposed to 
the ROS solutions. The greatest decrease in the replenishment rate of a depleted 
mucus layer (Figure 6) compared to control values was seen in the presence of 10 
mM peroxide (approximate replenishment rate = 6%/ h resting thickness vs. mean 
control value of 18.5%/ h, P <0.001). 50 mM (10.3%/ h, P<0.001) and 17.5 mM  
(12.8%/ h, P<0.01) peroxide all showed a significantly lower replenishment rate 
than the saline controls, with 5 mM (13.8%/ h) and 25 mM (15.5%/ h) peroxide 
having no significant effect. Release of red blood cells and plasma exudate was 
noted during the mucus thickness/replenishment measurement procedure for the 
depleted mucus layer under all concentrations of peroxide, as witnessed by a 
clouding over and graininess of the bathing fluid. 
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Discussion 
The rheological properties of pig colonic mucus gels measured in this study are 
similar to those previously described [42]. Throughout the frequency range 
studied (0.01-3.4 Hz), the storage (elastic) modulus (G′, characteristic of solid 
properties) was substantially greater than the loss (viscous) modulus (G′′,
characteristic of liquid properties), indicating a strong ‘gel-like’ behaviour for the 
gels.   
ROS treatment of colonic mucus gel did not significantly change the mechanical 
spectra of mucus gels, thus demonstrating the stability of mucus gel to ROS 
attack. After ROS treatment of the mucus gel, even with high concentrations of 
ROS, 50 mM H2O2, there were, (i), no significant changes in the moduli, G′ and 
G′′ throughout the frequency range tested, and (ii), no change in “gel-like” 
behaviour, i.e., tanδ had not significantly changed throughout the frequency range 
tested. This is in contrast to exposure of colonic mucus gel to agents, such as 
mercaptoethanol, that permeate the gel and destroy the polymeric structure of the 
constituent mucins causing complete collapse of gel structure [43]. 
Further evidence of lack of ROS damage to the gel comes from the absence of 
release of soluble glycoprotein and no change in the viscosity of the dispersed gel 
on ROS exposure. 
These studies demonstrated that the non-specific, non-mucin components within 
the mucus gel secretion have extensive ROS scavenging properties. Likely 
candidates for ROS scavengers are (i), intracellular antioxidants, (ii) bile salts 
(iii), antioxidant compounds derived from the diet, [31], (iv) cellular debris and  
bacterial and dietary polysaccharides. Proteins, such as albumin and lactoferrin, 
which have been found within mucus gel secretions, have a high affinity for free 
iron [32, 44]. Lipids and DNA are particularly sensitive to ROS attack (Halliwell 
& Gutteridge, 1999;[45], and would also provide important protection against 
ROS induced mucin degradation. It should be noted that protein- and DNA-rich 
13
fractions of the mucus gel are routinely measured (by 260/280nm 
spectrophotometry) and removed as part of the density gradient purification of 
mucins [28]. The other components mentioned here are also likely to be excluded 
by buoyant density in this procedure. 
In contrast to the colonic mucus gel ROS treatment of polymeric colonic mucin 
with 50 mM H2O2 caused a substantial breakdown of its polymeric structure and a 
loss of its viscous and gel-forming properties. Thus, after ROS treatment, there 
was a 97 % fall in mucin specific viscosity, a 10 fold drop in intrinsic viscosity 
and substantial degradation of the mucin as witnessed by small fragments with 
large relative mobilities on SDS PAGE. The methodology used here uses gels 
without a gradient on, and was initially designed to separate monomeric and 
polymeric mucins [46]. Further analysis of these degradation products would have 
given further detail with regard to the action of ROS on colonic mucins, but is not 
possible here, due to the incomplete separation of these degraded units. 
Polymeric colonic mucin incubated with 50 mM H2O2, generated mucin fragments 
of smaller molecular weight than mucin digested with papain alone, 
demonstrating that ROS, unlike proteolytic enzymes, are capable of accessing the 
heavily glycosylated regions of the mucin protein core. In addition ROS 
treatment, at the highest concentration, of papain generated mucin subunits 
produced fragments 60% smaller than those produced with 24 h ROS treatment of 
the polymeric mucin. This could suggest that exposed non-glycosylated protein 
regions of polymeric mucin are involved in ROS scavenging, thus reducing the 
extent to which the heavily glycosylated regions are fragmented. 
ROS treatment of the polymeric mucin produced loss of carbohydrate based on 
hexosamine analysis, indicating that the oligosaccharide chains were largely 
conserved.  There were changes in lectin binding pattern following ROS treatment 
of colonic mucin preparations, suggesting ROS had removed some of the 
outermost sugar structures (i.e. terminal sialic acid and GalNAc). Further from 
these sugars, a significant number of galactose and N-acetylglucosamine sugars 
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were lost. These results are in keeping with previous work [15, 16], where results 
suggested that the oligosaccharide chains of ovarian-cyst glycoproteins after 
hydrogen peroxide treatment were largely conserved, except for some loss of 
terminal sialic acid. The absence of a change in WGA binding after ROS 
treatment would appear to be in contrast to the decrease in sialic acid seen with 
MAL II and the decrease in GlcNAC binding with GSL-II and LEL, because 
WGA shows it’s major binding to GlcNAc but may also bind to sialic acid on 
some glycoconjugates. This discrepancy can be explained by examining the 
different specificities of the lectins, GSL-II recognises exclusively terminal 
GlcNAc whereas LEL prefers oligomers of GlcNAc and this explains the 
approximate four fold difference in binding of these lectins in the native mucin. 
Consequently changes in WGA binding are unlikely to mirror changes in LEL 
and GSL-II binding and because WGA is not uniquely sialic acid binding, it’s 
binding will not mirror changes in MAL II binding.  MAL-I has previously been 
reported to tolerate substitution of N-acetyl-lactosamine with sialic acid at the 3 
position of galactose, but not when the substitution of the sialic acid is at the 6 
position of galactose [47]. Changes between the binding patterns of MAL-I and 
MAL-II could be used as an initial marker of which sialic acid residues are being 
lost. However, in this study, we found no difference between the change in 
binding pattern of either lectin. 
While the ELLA methodology is dependent on access of the lectin binding sites to 
their target monosaccharides, the pattern described here suggests that the majority 
of free radical action on the mucin carbohydrate chains is a “nibbling away” of 
the most accessible sugars (i.e. a larger loss of terminal sugars, with subsequent 
loss of exposed monosaccharides thereafter. A more in depth analysis of 
carbohydrates and monosaccharides is necessary to fully characterise the effect of 
ROS on carbohydrate chains of colonic mucins, but fall outside the remit of this 
paper 
ROS treatment of polymeric colonic mucin with the 50 mM H2O2 mixture 
resulted in a significant 6 % loss of total protein content by weight.  ROS 
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treatment did not cause significant losses of serine, threonine and proline amino 
acids, which are mainly located within the heavily glycosylated, protease resistant 
regions of the secretory mucin protein core, while there were significant losses of 
amino acids associated with the protease sensitive, non-glycosylated and/or 
sparsely glycosylated regions of the mucin protein core.   These results suggest 
that heavy glycosylation protects these amino acids from destruction by ROS. 
The most notable change in amino acid content following ROS treatment of 
polymeric gastric and colonic mucin was a substantial loss of the minor amino 
acid histidine (63% loss after ROS treatment), indicating that histidine is 
particularly susceptible to destruction by ROS. Amino acids commonly located 
within the protease sensitive regions (i.e. histidine and cysteine) have previously 
been suggested to be very sensitive to ROS attack [48]. Histidine breakdown by 
ROS has previously been reported to yield aspartate residues [49]. Therefore, the 
increase of aspartate by 13% mirrors the loss of histidine residues well. 
Within these studies, it was not possible to measure cysteine and tryptophan 
residues. Both of these amino acids have been previously been suggested as 
targets of ROS degradation [15, 50]. While indirect measurement of the 
breakdown at cysteine units by ROS is suggested by loss of mucin polymeric 
structure (and therefore loss of cytseine-cysteine disulphide bridges), further 
analysis of both of these amino acid residues should be carried out in future 
studies. 
The native mucus gel is more resistant to ROS degradation than purified 
polymeric mucins, as evidenced by the viscosity studies. Although polymeric 
colonic mucin is not resistant to ROS degradation itself, its sacrifice may quench 
damaging ROS, thus protecting the mucosa, which can replace the damaged 
mucin by new secretion. 
The in vivo study tested the effects of a range of ROS concentrations that has been 
reported in human colonic luminal contents (mean 53µmol/ml of luminal 
content/h) [3]. 
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In the intact mucus barrier, the higher the level of ROS (above 5 mM), the greater 
the thinning rate of the mucus barrier. Interestingly, the 5 mM peroxide solution 
produced an increase in maximal mucus layer thickness, demonstrating a novel, 
beneficial role of low level ROS on colonic mucosal protection. This suggests an 
undefined mucosal protection mechanism, presumably where the ROS are sensed 
by the mucosa after permeating the mucus layer. However, this effect is swamped 
at high ROS levels as seen in animal colitis models. Whether this potentially 
protective effect of the low level ROS mixture is a result of a mucosal response to 
ROS directly, or to one of the components of the mixture itself is not clear, and 
requires further experimentation to elucidate. 
When the non-adherent mucus layer was removed, most of the concentrations of 
ROS had a detrimental affect on the replenishment rate of the mucus layer. This is 
likely to be due to damage causing attenuation of the synthetic potential of the 
mucosa. The 25mM ROS result is difficult to interpret with no decrease in 
replenishment rate but this could in part be explained by release of plasma 
exudate and cell debris into the mucus layer [11] making mucus thickness 
measurements less reliable. At least the same serverity of mucosal damage would 
be expected with 50mM, but here the effect of plasma and debris may be over 
ridden by the levels of solubilised mucus. These data suggests that ROS generated 
to these levels in the colon will cause mucosal damage to a healthy mucosa, or to 
one that has already undergone such pathological change as that seen in ulcerative 
colitis. 
The decrease in mucus thickness produced by ROS is not unexpected, and fits in 
with results obtained previously using in vitro models [15-19], and we have 
demonstrated that the colonic mucus layer barrier properties are affected by ROS 
presence in vivo. Whether this is occurring as a result of an increased rate of 
mucus degradation, or a decrease in rate of mucus secretion is unsure.  
In conclusion this study has shown that mucus gel scraped from the pig colon is 
resistant to damage by ROS and must therefore have extensive ROS scavenging 
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properties. These properties reside mainly in non-mucin components which 
augment mucin’s ability to quench ROS many fold. Both the carbohydrate and 
protein regions of mucin are important in ROS scavenging.  
Low levels of luminal colonic ROS increase the innate protection afforded to the 
mucosa by the mucus barrier in vivo. Nitric oxide and ROS has previously been 
shown to act as a mucus secretagogue in the gastric mucosa, [51]. Studies in 
cultured normal human bronchial cells have suggested that low levels of ROS 
effect an up-regulation of MUC5AC expression via TGFα pathways [52].  If 
similar mechanisms govern colonic mucin expression, then this effect would offer 
a potential pathway for our observations.  Higher levels of ROS lead to reduction 
of maximal mucus layer thickness, and/or a release of blood cells and plasma 
components in mucus layer that is already depleted. 
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